← All indications
Inflammatory Breast Neoplasms
Metastatic breast cancer characterized by EDEMA and ERYTHEMA of the affected breast due to LYMPHATIC METASTASIS and eventual obstruction of LYMPHATIC VESSELS by the cancer cells.
Drugs by status
Phase 3 trials (18)
Phase 2 trials (18)
Phase 1 trials (8)
Other trials (1)
Organizations
Organization Involved with Phase 3 Indications (21)
- Celgene
- Amgen
- Roche
- GlaxoSmithKline
- Teva
- Vifor Inc.
- National Cancer Institute (NCI)
- Anglo Celtic Cooperative Oncology Group
- Cancer and Leukemia Group B (CALGB)
- Institut Bergonié
- Institut Paoli-Calmettes
- Scottish Cancer Therapy Network
- Swiss Group for Clinical Cancer Research
- University of Glasgow
- UNICANCER
- Jiao Tong University
- Nationale Centrum für Tumorerkrankungen
- European Organisation for Research and Treatment of Cancer
- German Breast Group Forschungs GmbH
- AGO Germany
- Swedish Breast Cancer Group
Organization Involved with Phase 2 Indications (31)
- Incyte
- Eisai
- Bristol-Myers Squibb
- Merck
- Eli Lilly
- Genentech
- Pharmacia & Upjohn
- Aventis
- Sanofi
- Novartis
- BerGenBio ASA
- Boehringer Ingelheim
- Puma Biotechnology, Inc.
- Canadian Cancer Trials Group
- Cancer Research Network
- Harvard University
- University of Washington
- New York University
- Northwestern University
- Rutgers University
- Southwest Oncology Group
- Thomas Jefferson University
- University of Medicine and Dentistry of New Jersey
- University of Toronto
- Mayo Clinic
- SCRI Development Innovations
- City of Hope National Medical Center
- University of Texas at Houston
- Hospital Auxilio Mutuo
- University of Duisburg-Essen
- +1 more
Organization Involved with Phase 1 Indications (6)